InDevR

About InDevR

InDevR is a life sciences tools company specializing in analytical technologies for the vaccine and biotherapeutics markets. The firm was founded in 2003 by Dr. Kathy Rowlen, John Birks, and Laura Kuck, and is headquartered in Boulder, Colorado. Dr. Rowlen, the company's CEO, transitioned from a distinguished academic career as a Professor of Chemistry at the University of Colorado, bringing deep scientific expertise to the company's leadership. This foundation in academic research is a core element of the company's DNA, enabling the translation of fundamental science into commercially viable products.

The company's business is centered on the development and manufacturing of advanced analytical instruments and consumable assay kits that accelerate vaccine and biotherapeutic development and production. InDevR serves a global client base of pharmaceutical companies, biopharmaceutical manufacturers, and research institutions. Revenue is generated through the sale of these products and the provision of testing and custom services. The business model is bolstered by a combination of commercial sales, significant non-dilutive grant funding from organizations like the NIH and BARDA, and venture capital. The company has successfully raised $16 million over multiple funding rounds, including a $9 million Series B in 2023 led by Adjuvant Capital and bioMérieux.

InDevR's flagship product line is the VaxArray® platform, a microarray-based system for multiplexed quantification of critical quality attributes like protein concentration and potency. This platform offers specific kits for various vaccines, including influenza, measles, rubella, polio, and pneumococcal, as well as for mRNA-based therapeutics. A key benefit of the VaxArray system is its speed and efficiency, providing results significantly faster than traditional methods like the single radial immunodiffusion (SRID) assay. Another principal offering is the CypherOne system, which provides digital imaging and automated interpretation of hemagglutination assays, a common method for influenza virus quantification. These tools are designed to streamline quality control and manufacturing processes for vaccine developers, ultimately reducing the time and resources required to bring new vaccines to market.